Research programme: wound and pain therapeutics - National Pharmaceuticals

Drug Profile

Research programme: wound and pain therapeutics - National Pharmaceuticals

Alternative Names: GLB333

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Globe Laboratories
  • Developer National Pharmaceuticals Corp
  • Class Cytokines; Growth factors; Interleukins; Recombinant proteins
  • Mechanism of Action Cytokine inhibitors; Growth modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Pain; Wounds

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Wounds in Canada
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Canada
  • 22 Mar 2011 GLB 333 licensed to National Pharmaceuticals Corp worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top